Cell line · CVCL_IU14
Papers38
1 to 20 of 38
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| BRCA1 Mutation-Recognizing Tetrahedral Framework Nucleic Acid Nanoplatform Enables Coordinated PARP/WEE1 Inhibition and STING-Associated Antitumor Immunity in Ovarian Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LOX-1 mediated lipid peroxidation leads to dysfunction of tumor infiltrating CD8+ T cells in ovarian cancer. | Redox Biol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Temporal Immune and Metabolic Shifts Drive the Anti-Tumor Efficacy of Resiquimod-Loaded Nanoparticles in Peritoneal Carcinomatosis. | Adv Healthc Mater | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Framework for evaluating in vitro vasculogenic mimicry using structural and metabolic parameters. | Cell Rep Methods | 2026 | Its Methods give the RRID and name the line | PubMed | |
| RelB drives integrin-mediated stress tolerance and relapse in high-grade serous ovarian cancer. | Cell Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| VISTA+ Neutrophils Contribute to Platinum Resistance by Suppressing CD8+ T Cells in High-Grade Serous Ovarian Cancer. | Cancer Immunol Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Malassezia restricta-Derived Extracellular Vesicles Drive Ovarian Cancer Progression Through JAK2/STAT3-Mediated M2 Macrophage Polarisation. | Microb Biotechnol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Cutibacterium acnes-Derived Extracellular Vesicles Promote Epithelial Ovarian Cancer Progression by Activating the KEAP1-NRF2 Antioxidant Pathway to Suppress Ferroptosis. | Microb Biotechnol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. | Sci Adv | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Combination of Tripterygium glycosides and Lactobacillus paracasei sensitises epithelial ovarian cancer to cisplatin via downregulating Keap1-Nrf2-GPX4 signalling pathway. | Cell Mol Biol Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Platelets induce VISTA expression and modulate the ovarian tumor microenvironment. | Platelets | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Galangin-loaded biomimetic dendritic cells membrane nanovaccine reprograms the ovarian cancer microenvironment via Stat3/IDO1/AhR axis to boost immunotherapy. | Mater Today Bio | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Mapping CSC-Mediated Ovarian Cancer Chemoresistance via CXCR4-PET to Guide Precision Cisplatin Re-Sensitization Therapy. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Chromobox 2 Inhibition: A Novel Activity of Alisertib, an Aurora A Kinase Inhibitor. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer. | Signal Transduct Target Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| IL7R remodels immunosuppression tumor microenvironment and promotes macrophage polarization by regulating NF-κB/CXCL1 axis in ovarian cancer. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Differential regulation of FADS2 by EZH2 reveals a metabolic vulnerability in ovarian cancer treatment. | EBioMedicine | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting lipid scrambling potentiates ferroptosis and triggers tumor immune rejection. | Sci Adv | 2025 | Its Methods give the RRID and name the line | PubMed | |
| CD81 Aggravates Ovarian Cancer Progression via p-Cresyl Sulfate-Mediated Mitophagy in Tim4+ Tumour-Associated Macrophages. | J Cell Mol Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Dexmedetomidine alleviates the pro-tumor activity of perioperative stress in tumor-bearing mice: an alternative approach of psycho-physiological intervention. | World J Surg Oncol | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_IU14/papers